i
Antiretroviral drug exposure in urethral and glans surface sampling of the penis
-
8 12 2021
-
-
Source: J Antimicrob Chemother. 76(9):2368-2374
[PDF-243.81 KB]
Details:
-
Alternative Title:J Antimicrob Chemother
-
Personal Author:
-
Description:Background:
HIV exposure to penile tissues provides a risk of acquisition among men, yet studies evaluating penile antiretroviral (ARV) drug distribution have been lacking. We measured ARVs on urethral and glans surface swabs collected following a dose of tenofovir alafenamide, emtricitabine, elvitegravir, darunavir and cobicistat.
Methods:
Thirty-five HIV-negative male participants provided urethral swabs, glans swabs, rectal swabs, blood and urine up to 96 h following a single dose of tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat and darunavir. ARVs were measured by liquid chromatography–mass spectrometry with a lower limit of detection (LOD) of 1 ng/swab for swabs and 10 ng/mL for plasma and urine. Concentrations are reported as median and range.
Results:
Urethral swab emtricitabine and darunavir concentrations peaked at 4 h for emtricitabine (36 ng/swab; 3–307 ng/swab) and 8 h for darunavir (25 ng/swab; 2–52 ng/swab). Glans swab emtricitabine and darunavir concentrations peaked 24 h after dosing (emtricitabine 14 ng/swab,
Conclusions:
We document ARV dosing in the urethra and on the glans surface with high drug concentrations noted for emtricitabine and darunavir and lower tenofovir and elvitegravir concentrations. Data suggest a potential protective role of urethral emtricitabine or darunavir against penile HIV acquisition.
-
Subjects:
-
Source:
-
Pubmed ID:34007982
-
Pubmed Central ID:PMC10134741
-
Document Type:
-
Funding:
-
Volume:76
-
Issue:9
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
